• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Stevanato Group Launches After-sales Service Offering

    X-Chem Acquires IntelliSyn and AviSyn

    Aphena’s $21M Cookeville Expansion Nears Completion

    BioMed X, Janssen Enter Oral Drug Delivery Alliance

    Care Access Research, AstraZeneca Partner on COVID-19 Antibody Trial
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Aphena’s $21M Cookeville Expansion Nears Completion

    PromoCell Receives EXCiPACT Certification

    Civica to Build an Essential Medicines Manufacturing Facility in Virginia

    Humanigen, Emergent Enter Covid-19 Partnership

    Samsung Bioepis Opens New Headquarters
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Aphena’s $21M Cookeville Expansion Nears Completion

    Civica to Build an Essential Medicines Manufacturing Facility in Virginia

    WDSrx Expands Warehouse Network

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    The Future of Clinical Trials Series: Part II

    X-Chem Acquires IntelliSyn and AviSyn

    Care Access Research, AstraZeneca Partner on COVID-19 Antibody Trial

    Caprion-HistoGeneX Rebrands as CellCarta

    Humanigen, Emergent Enter Covid-19 Partnership
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    PCI Pharma Services

    Syngene

    Cytovance Biologics

    Alcami
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Almac Group

    Alcami

    Cytovance Biologics

    Baxter BioPharma Solutions

    PCI Pharma Services
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    FDA Watch

    Continuous Manufacturing and its Regulatory Challenge

    ...

    Continuous Manufacturing and its Regulatory Challenge
    Related CONTENT
    • Mogene
    • Vetio Animal Health
    • It’s Showtime!
    • FDA Approves Antibiotic for Community-Acquired Pneumonia
    • Syapse, FDA Announce RCA Using Real-World Evidence
    José L. Toro, PhD, Lachman Consultants09.16.19
    Batch manufacturing (BM) of solid oral dosage forms has been around for well over half a century and will very likely continue to be around for a long time to come. BM is based on a sequence of start-and-stop individualized manufacturing steps. At each stop of an individualized manufacturing step, generally there are numerous quality inspections, quality control (QC) analysis, or both. The industry has proven without a doubt that this approach to manufacturing solid oral dosage forms has been tried and true.

    So, what is the buzz about continuous manufacturing (CM)? What benefits does it bring to the manufacturer and what regulatory challenges are there to overcome? This article discusses the current thinking on the benefits of CM and the regulatory hurdles a manufacturer has to overcome.

    Batch vs. continuous processes
    In a BM process, the manufacturer develops a multi-step and multi- vessel or container process pending the next step in the process. After each discrete step, the intermediate is held, pending the quality testing results. After successfully completing this discrete intermediate step, the manufacturer then proceeds to either charge a new vessel or re-activate the current vessel the intermediate was held in to start the next processing step.

    The effect of continuously stopping, waiting for results, and reinitiating the process can be extremely time consuming, creates manufacturing equipment idle time and could also create unwanted quality attributes of the intermediate, such as powder segregation. Cost and quality are only two factors mentioned here but there others that make BM somewhat antiquated.

    What is CM? CM is not novel and has been used by many industries for numerous years. These uses and industries include petrochemical, single-unit flow reactor operations in active pharmaceutical ingredient (API) processes and more notably the biomanufacturing operations that use bioreactors for biological compounds, to name a few.

    Pharmaceutical products manufactured using CM move through their respective manufacturing steps non-stop within a specific facility or location within a facility. CM is a process where raw materials are moved through an assembly of vessels or reactors that are fully integrated components. CM is a highly automated process which utilizes automated production steps that successfully integrate either chemical or formulation steps to work together to provide an end-to-end product with minimal intervention and stoppage of the process.

    To enable CM end-to-end processes with minimal or no intervention, the manufacturer and the corresponding manufacturing process has to have the right technology to measure, in real time, the optimum endpoint of a specific step in the process before moving on to the next step in its journey to the end. Sensor technology, automation and in-line process analytical technology to measure the critical process parameters and critical quality attributes are instrumental in designing a CM process. Newer versions of Delta V technology that have embedded advanced control applications are making CM less complicated to provide information from multiple sources and carry out a closed-loop control system in a single self-contained vessel.1 Two proven process analytical technologies (PAT) are non-spectroscopic determination of active substance concentration during feeding and the other is a spectroscopic measurement of content uniformity during the process.2

    When manufacturing steps are carried out in a continuous manner, fully characterizing the properties of each raw material used is of greater significance than in BM. Each raw material’s ability to be processed continuously needs to be characterized.2 The ultimate goal of CM is to take all the raw materials in a single production line starting from one end and finishing with a final dosage form (tablet or capsule) out the other.

    Who are some of the early adopters of CM? From 2015 to date, at least four solid oral dosage drugs (OSD) manufactured using CM have been approved by the U.S. Food and Drug Administration (FDA). Three out of the four approved OSDs were new molecular entities and the fourth one was a conversion from BM to CM. Table 1 illustrates the FDA approvals of OSDs produced by continuous manufacturing.


    Table 1. FDA Approved Oral Solid Dosage Drugs Manufactured by Continuous Manufacturing3

    Regulatory challenges
    An FDA statement published in February 2019 made, by then FDA Commissioner Scott Gottlieb, MD, and Janet Woodcock, MD, Director of the FDA’s Center for Drug Evaluation and Research (CDER) made it clear what direction the FDA is taking toward CM. The statement read:

    “We’re encouraged to see a growing number of companies embracing CM. It’s a key step towards promoting drug quality and improving the efficiency of pharmaceutical manufacturing. We’ve worked hard to help industry develop the tools to start advancing these goals. The FDA is committed to helping more companies advance these CM platforms owing the public health benefits of these more modern approaches. We support the early adopters that are embracing this innovative technology, and we look forward to working with other interested companies.”4

    What are these expressed benefits that the FDA Commissioner and the Director of CDER are emphasizing? One of the anticipated benefits of CM is the ability to match supply with demand by  customizing your lot size to your client’s requirements. Another benefit in using uninterrupted production processes is the elimination or potential significant reduction of the dreadful “hold times” which are established during BM and require analytical and/or microbiological testing and validation before proceeding to the next discrete step. This extends your production cycle time.
    Other benefits of CM are:
    • the potential to increase speed and agility for developing new products/processes5
    • CM could offer a safer process, eliminating the transition steps where the intermediate is discharged, held, recharged into another vessel6
    • CM can be an advantage in developing and providing new drugs for clinical development by shortening formulation development5
    • CM can provide the manufacturer a reduced risk of human error. CM may involve fewer manufacturing personnel in the production process from beginning to end8
    • CM can offer a significant production cycle time reduction. The FDA estimates that some drugs can take over a month to produce using BM processes which if made by CM could be completed in a few days.8
    • CM can offer the manufacturer added assurance to respond to market demands by using a “just in time” approach instead of the conventional method of keeping large finished goods or Works in Progress in the warehouse just in the event of demand surges5
    • CM could represent a smaller footprint in the manufacturing facility which, in turn, could free up valuable qualified manufacturing rooms for other products.6
    Some of the hurdles a manufacturer needs to overcome are:
    • for existing approved products, the current production lines/trains are tied to the regulatory approvals that were defined in the original submission and moving to CM requires a new submission.
    • not having a global harmonized regulatory approval process for CM makes it more difficult when addressing country specific vs global launches of a product.
    • not having global harmonized regulatory approval process could lead to prolonged approval times for medically necessary drugs and could drive the manufacturer to choose the more conventional batch process to get approval of the new drug.
    • the selection and development of flow chemistry transformations, difficulties processing dry solids, and solid-laden fluids present a challenge in CM.6
    • the lack of appropriate bench and pilot scale equipment, and development of control strategies are significant hurdles a manufacturer needs to overcome.6
    • developing a comprehensive QbD process requires experienced professionals within the organization to achieve the desired CM process.
    As the industry moves towards CM, the FDA is providing the resources and guidances necessary for manufacturers to make the right decisions for their products and processes.

    In 2017, the FDA issued a new guidance to support and stimulate industry to consider new emerging technologies entitled, “Advancement of Emerging Technology Applications for Pharmaceutical Innovation and Modernization.” This guidance provides the platform for industry to seek: “the development of pharmaceutical innovation and modernization, such as a more robust drug product design and improved manufacturing with better process control, thereby leading to improved product quality and availability throughout a product’s lifecycle.”8 The program offers the manufacturer to have early engagement and additional meeting opportunities with the FDA. During these meetings the manufacturer can discuss: “(1) product or manufacturing design and development issues and (2) submission content related to the emerging technology.”7  

    In 2019, the FDA issued a new draft guidance entitled “Quality Considerations for Continuous Manufacturing,” which provides FDA’s current thinking on quality considerations for CM of small molecules, solid oral drug products that are regulated by CDER.9 In this draft guidance, the FDA “focuses on scientific and regulatory considerations that are specific or unique to continuous manufacturing. These considerations include process dynamics, batch definition, control strategy, pharmaceutical quality system, scale-up and bridging of existing manufacturing to continuous manufacturing.”8

    The FDA strongly encourages the manufacturer to understand its process dynamics as a function of the attributes of the input materials (material flow and potency properties), process conditions, equipment design elements, the ability to enable material traceability (how to preserve and access the identity and attribute of a material throughout the system) during the manufacturing process and establishing a sound risk assessment of the continuous manufacturing process. Hence, a comprehensive QbD process.9

    One common approach to characterizing material flows throughout the process is the characterization of residence time distribution (RTD) for individual equipment trains and the fully integrated system.10 RTD models are vital to better understand the process dynamics and adequately support process monitoring throughout the continuous manufacturing process. The RTD models can be used to monitor the traceability of raw material, intermediates and even finished goods when the desired specifications are not met.9 

    In summary, CM can provide quicker response to demand, potential reductions in manufacturing cost and facilities investments. Also, reduction in Work in Progress inventories are conceivable, the ability to reduce production cycle times, and improved quality of the finished product can be achieved by reducing the manipulation of intermediates. The FDA is open to emerging technologies and has issued recent guidance documents that provide those of us interested in the industry to consider and implement this technology in our operations. Automation, understanding your process by using a comprehensive QbD approach, and the patience to potentially expect prolonged approval cycles can ultimately give a better product to the patient and provide potential/significant manufacturing cost saving. 

    References
    1. Neil, S., “Pharma Catches on to Continuous Manufacturing”, Automation World, December 6, 2017, http://www.automationworld.com/article/technologies/dcs/pharma-catches-continuous-manufacturing
    2. ECA Academy, “USP article on pharmaceutical continuous manufacturing”,  – November 14, 2018, https://www.gmp-compliance.org/gmp-news/usp-article-on-pharmaceutical-continuous-manufacturing
    3. Douglas B. Hausner,PhD, Christine M.V. Moore, PhD, “Continuous Manufacturing Current Status”, Pharmaceutical Engineering, May/June 2018, http://ispe.rog/pharmaceutical-engineering/many-june-2018/continuous-manufacturing-current-status
    4. FDA, “FDA statement on FDA’s modern approach to advanced pharmaceutical manufacturing,” February 26, 2019, https://www.fda.gov/news-events/press-announcements/fda-statement-fdas-modern-approach-advanced-pharmaceutical-manufacturing.
    5. Pagliarulo, N., “Pharma’s slow embrace of continuous manufacturing”,  BioPharma Dive, September 24, 2018, http://www.biopharmadive.com/news/pharmas-slow-embrace-of continuous-manufacturing/532811/ (quoting David Pappa, Head of Technical Services and Manufacturing Sciences, Eli Lilly and Company)
    6. Mascia, S., et.al., “End-to-End Continuous Manufacturing of Pharmaceuticals: Integrated Synthesis, Purification, and Final Dosage Formation”,Angewandte Chemie International Edition, 52(47):12359-12363, November 2013. 
    7. Pagliarulo, N., “Pharma’s slow embrace of continuous manufacturing”,  BioPharma Dive, September 24, 2018, http://www.biopharmadive.com/news/pharmas-slow-embrace-of continuous-manufacturing/532811/ (quoting Markus Hayek, Managing Director at Accenture Strategy)
    8. FDA, “Advancement of Emerging Technology Applications for Pharmaceutical Innovation and Modernization: Guidance for Industry”, September 2017, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/advancement-emerging-technology-applications-pharmaceutical-innovation-and-modernization-guidance
    9. FDA, “Quality Considerations for Continuous Manufacturing: Guidance for Industry”, Draft, February 2019, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/quality-considerations-continuous-manufacturing
    10. Escotet-Espinoza, M. Sebastian, et. al., “Effects of tracer material properties on the residence time distribution (RTD) of continuous powder blending operations. Part I of II: Experimental evaluation”, Powder Technology,  342: 744 – 763, January 2019.

    José L. Toro, PhD
    Lachman Consultants

    José L. Toro, PhD, is a Director in the Compliance Practice at Lachman Consultants who has extensive R&D Quality, and Quality Operations experience in the pharmaceutical industry. Dr. Toro specializes in the transformation of Quality and Technical Services organizations including Quality Systems, global implementations, corporate auditing, technology transfer and plant operations. He has a broad knowledge of regulatory compliance and quality control. Dr. Toro is well versed in FDA, MHRA, IMB, ANVISA; Japan and Korean inspections. He is highly experienced in manufacturing technologies for multiple dosage forms and associated processes; aseptic operations, complex prefilled syringes, extended-release solids, liquids, semi-solids, parenterals, medical devices, combination products, as well as bulk operations. Dr. Toro co-authored the PDA Technical Report (TR 60-2) on Solid and Semi-Solid Process Validation.
    Related Searches
    • API
    • Manufacturing
    • Development
    • end-to-end
    Suggested For You
    Mogene Mogene
    Vetio Animal Health Vetio Animal Health
    It’s Showtime! It’s Showtime!
    FDA Approves Antibiotic for Community-Acquired Pneumonia FDA Approves Antibiotic for Community-Acquired Pneumonia
    Syapse, FDA Announce RCA Using Real-World Evidence Syapse, FDA Announce RCA Using Real-World Evidence
    Carbogen Amcis API Site Passes FDA PAI Carbogen Amcis API Site Passes FDA PAI
    Considerations for Analytical Method Validation Lifecycle Controls Considerations for Analytical Method Validation Lifecycle Controls
    Cytovance Completes Second FDA PAI of Oklahoma Facilities Cytovance Completes Second FDA PAI of Oklahoma Facilities
    Serialization and the Rest of Us Serialization and the Rest of Us
    Effective Post Market Supplier Strategy for Combination Products Effective Post Market Supplier Strategy for Combination Products
    FDA Inspection of Asymchem Dunhua 1 API Manufacturing Facility is Successful FDA Inspection of Asymchem Dunhua 1 API Manufacturing Facility is Successful
    Tedor, Adial Enter Manufacturing Collaboration Tedor, Adial Enter Manufacturing Collaboration
    FDA Approves TraceLink DSCSA Pilot Submission for Network Solutions FDA Approves TraceLink DSCSA Pilot Submission for Network Solutions
    Nitrosamines Nitrosamines
    Process Validation in Biologics Development Process Validation in Biologics Development

    Related FDA Watch

    • The Importance of Hypothesis Testing During Investigations

      The Importance of Hypothesis Testing During Investigations

      Why it is critical to have controls in place during out-of-specification investigations to provide quality assurance.
      Paul Mason, PhD, Lachman Consultants 11.17.20

    • Biologics, Proteins, Vaccines | Regulatory Affairs
      Ensuring Manufacturing Continuity for Essential Medicines

      Ensuring Manufacturing Continuity for Essential Medicines

      Applying the principles of Quality Risk Management to get medicines to market faster.
      John Darby, M.Sc., Senior Director, Lachman Consultant Services, Inc. 09.09.20

    • Biologics, Proteins, Vaccines
      Pharma’s Fight Against the Coronavirus Pandemic

      Pharma’s Fight Against the Coronavirus Pandemic

      A look at the pharma industry’s concerted effort to develop vaccines against the SARS-CoV-2 virus and therapeutics to treat COVID-19.
      Keith O. Webber, Lachman Consultant Services, Inc. 07.15.20


    • Information Technology | Regulatory Affairs
      Data Integrity: Beyond Electronic Records

      Data Integrity: Beyond Electronic Records

      Get your Data Integrity house in order
      Tim Rhines, Ph.D., Director, Lachman Consultant Services, Inc. 05.05.20

    • Regulatory Affairs
      Inquiring Minds Want to Know, Just Ask FDA

      Inquiring Minds Want to Know, Just Ask FDA

      What you need to know prior to submission
      Michelle Ryder, Lachman Consultant 04.01.20

    • Regulatory Affairs
      The Art of Filing NDA/ANDA Post-Approval Changes to the FDA

      The Art of Filing NDA/ANDA Post-Approval Changes to the FDA

      Some tips to make your trip along the regulatory pathway to report manufacturing changes easier.
      Amy Schutte, Senior Associate, Lachman Consultant Services 03.04.20


    • Regulatory Affairs
      Inactive Ingredients: Where Guidance Needs to Meet Data

      Inactive Ingredients: Where Guidance Needs to Meet Data

      Looking at FDA’s most recent draft guidance and the struggle with inactive ingredients.
      Sharif Ahmed, Lachman Consultants Services 10.15.19

    • QA/QC | Validation
      Considerations for Analytical Method Validation Lifecycle Controls

      Considerations for Analytical Method Validation Lifecycle Controls

      ICH is set to implement new regulatory guidance dedicated to analytical method development
      Paul Mason, PhD, Lachman Consultants 07.15.19

    • Regulatory Affairs
      Effective Post Market Supplier Strategy for Combination Products

      Effective Post Market Supplier Strategy for Combination Products

      Combinations are typically designed, developed and maintained under a robust contract manufacturing process
      Lori-Ann Woodard CBA, CQE, CSQE, Lachman Consultant Services 06.13.19


    • QA/QC
      Nitrosamines

      Nitrosamines

      How to address these unwelcome guests in the pharmaceutical world
      Aloka Srinivasan, Ph.D., Lachman Consultant Services 05.07.19

    • Regulatory Affairs
      KASA to Support Generic Drug Review

      KASA to Support Generic Drug Review

      FDA expects the new system to advance OPQ’s focus on pharmaceutical quality, the foundation for ensuring the safety and efficacy of drugs.
      Sharif Ahmed, Lachman Consultant Services 04.05.19

    • Regulatory Affairs
      FDA’s Interpretation of the “Deemed to be a License” Provision of the Biologics Price Competition an

      FDA’s Interpretation of the “Deemed to be a License” Provision of the Biologics Price Competition an

      A look at how the FDA will administer the transition of NDAs to BLAs
      Keith Webber, Ph.D., Lachman Consultant Services 03.06.19


    • Regulatory Affairs
      Reporting CPPs to FDA

      Reporting CPPs to FDA

      Importance of identifying critical process parameters in original submissions to FDA.
      Aloka Srinivasan, Ph.D. Lachman, Consultant Services 10.10.18

    • Regulatory Affairs
      FDA and Field Alert Reports

      FDA and Field Alert Reports

      Analysis of “Field Alert Report Submission Questions and Answers Guidance for Industry”
      Constance Richard-Math, Lachman Consultants 09.11.18

    • Regulatory Affairs
      Elemental Impurity & Risk Assessment

      Elemental Impurity & Risk Assessment

      An update on the retirement of USP General Chapter <231>.
      Paul Mason, Lachman Consultants 07.20.18

    Trending
    • Integrated Continuous Manufacturing ICM
    • Humanigen, Emergent Enter Covid-19 Partnership
    • Samsung Bioepis Opens New Headquarters
    • CDMO Northway Biotech Expands In U.S.
    • CONTINUUS Awarded $69.3M DoD Grant
    Breaking News
    • Stevanato Group Launches After-sales Service Offering
    • X-Chem Acquires IntelliSyn and AviSyn
    • Aphena’s $21M Cookeville Expansion Nears Completion
    • BioMed X, Janssen Enter Oral Drug Delivery Alliance
    • Care Access Research, AstraZeneca Partner on COVID-19 Antibody Trial
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    MIND and Mediterranean Diets Linked to Later Onset of Parkinson’s Disease
    Kerry Launches Web-Based Tool for Plant-Based Formulation Challenges
    Wiley’s Finest Earns Accolades for Taste of Omega-3 Products
    Coatings World

    Latest Breaking News From Coatings World

    Scott McLaughlin to Race in PPG Colors During Rookie INDYCAR Season
    Vink Chemicals Offers parmetol PSG
    Minwax Announces Vintage Blue as 2021 Color of the Year
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Butterfly Network Appoints New Leader
    BD Names Chairman of Board
    Interplex Acquires OCP Group
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Stevanato Group Launches After-sales Service Offering
    X-Chem Acquires IntelliSyn and AviSyn
    Aphena’s $21M Cookeville Expansion Nears Completion
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    The Estée Lauder Companies Announces Game-Changing Sustainability Goals for Travel Retail
    Aura Introduces Customizable Hair Care
    Corpack Creates Custom Packaging for Marlies Möller Hair Care Line
    Happi

    Latest Breaking News From Happi

    Nice-Pak Receives EPA Approval for Disinfectant Wipes
    Symrise Shares 2020 Sales Figures
    Harry’s Launches ‘Headquarters’
    Ink World

    Latest Breaking News From Ink World

    Epson Partner Creates Label Applicators for Pharmaceutical Products
    Smurfit Kappa Sets New Sustainability Targets with Better Planet 2050
    Paragon Expands Direct Mail Capabilities with Ricoh Pro VC70000
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Great Lakes Label debuts new website
    Epson partner creates label applicators for pharmaceutical products
    ACTEGA removes chemicals from laminating adhesives
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    American Made Production Equipment for Mask Manufacturers
    Kimberly-Clark Releases Q4, Full Year Results
    Freudenberg to Establish Apparel Interlining Competence Centers
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Spinal Elements' Lucent XP-Curved Expandable TLIF Gains FDA Nod
    FDA OKs OrthoSpin's 2nd Gen Robotic, Digital External Fixation System
    Nextremity Solutions Enters Supply Agreement with Fort Wayne Metals
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    North American Semiconductor Equipment Industry Posts December 2020 Billings
    First Solar Signs Definitive Agreement to Sell US Development Platform to Leeward
    PRINTING United Alliance Announces TAGA Presents Virtual Event

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login